checkAd
    Startseite > Aktien > Alector > Nachrichten
    Alector Aktie
    4,7800
     
    EUR
    +0,42 %
    +0,0200 EUR
    Letzter Kurs 18.04.24 Tradegate
    4,7600
     
    EUR
    528 STK
    Geldkurs 14:42:03
    4,8000
     
    EUR
    521 STK
    Briefkurs 14:42:03
    ISIN: US0144421072 · WKN: A2PCBM · SYM: 0Z2 · USA

    Neueste Nachrichten

    Alector to Participate in Upcoming Healthcare Conferences
    28.02.24 · globenewswire · Alector
    Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    27.02.24 · globenewswire · Alector
    Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
    20.02.24 · globenewswire · Alector
    Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
    08.02.24 · globenewswire · Alector
    FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
    07.02.24 · globenewswire · Alector
    Alector Announces Closing of Public Offering
    19.01.24 · globenewswire · Alector
    Alector Announces Pricing of Public Offering of Common Stock
    17.01.24 · globenewswire · Alector
    Alector Announces Proposed Public Offering of Common Stock
    16.01.24 · globenewswire · Alector
    Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
    28.11.23 · globenewswire · Alector
    Alector to Participate in the Stifel Healthcare Conference
    08.11.23 · globenewswire · Alector
    Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
    07.11.23 · globenewswire · Alector
    Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
    27.10.23 · globenewswire · Alector